<DOC>
	<DOCNO>NCT01730612</DOCNO>
	<brief_summary>Main objective : To determine optimal molar dos biospecific antibody TF2 68 Ga-IMP-288 optimal time pretargeting immuno-PET patient breast carcinoma . Secondary objective : To study sensitivity immuno-PET , compare performance standard image method , evaluate safety 150 MBq 68 Ga-IMP-288 ; study development immunization TF2 complex TF2-IMP-288 ;</brief_summary>
	<brief_title>ImmunoTEP au 68-Ga- IMP-288 Patients With Recurrence HER2 Negative Breast Carcinoma Expressing CEA</brief_title>
	<detailed_description>- 4 5 cohort 3 patient receive different dos TF2 IMP-288 different interval time . A last cohort ( 4 5 ) : maximum 21 additional patient optimal schedule . Cohort I : TF2 120 nmol / 6 nmol IMP-288 / 24 hour Cohort II : base result cohort I : 1 . Good signal tumor high background : increase interval time , 120 nmol TF2 / 6 nmol IMP-288 / 30 hour 2 . Low signal tumor : reduction interval time , 120 nmol TF2 / 6 nmol IMP-288 / 18 hour 3 . Good signal tumor good background signal : dose reduction , 60 nmol TF2 / 3nmol IMP- 288 / 24 hour Cohort III : base result cohort II : - Good signal tumor : dose reduction , 120 nmol TF2 / 3 nmol IMP-288 / 30 h Cohort IV : base result cohort III Cohort V : Based result cohort IV • A last Cohort ( VI ) : 19 patient optimal schedule injection : 120 nmol TF2 / 3 nmol IMP-288 / 30 h 120 nmol TF2 / 6 nmol IMP-288 / 30 h • In four week prior immuno-PET : - Clinical examination , - CEA CA15-3 , - thoraco abdominal pelvic scan , bone scan , FDG-PET , - immunohistochemistry ACE tumor possible , - Anti-Antibodies patient already receive MAb , - pregnancy test within 2 day prior immuno-PET , - ( creatinine &gt; 2.5 normal ) D0 : Injection TF2 D1 D4 : injection 68 Ga-IMP-288 ( depend cohort ) D0 D4 : pharmacokinetics , image Evaluation 1 month Immuno-PET : • Assessment clinical oncologist - histological biopsy / surgery perform accord result image assessment potential clinical impact Evaluation 3 6 month immuno-PET : base result immuno-PET , evaluation therapeutic decision oncologist , - Imaging ( ultrasound , bone scintigraphy , CT PET FDG ) , - marker - Anti-Antibody Search - For patient cancer treatment new immuno-PET propose</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Breast carcinoma , HER2 + ( Dako ) HER2 + ( fish ) metastatic least treatment current consensus ≥ 18 year Negative pregnancy test woman childbearing age . Women childbearing age take effective contraception continuously 3 month . Karnofsky ≥ 70 ECOG 01 •• ACE tumor immunohistochemistry positive plasma CEA ≥ 10 ng / mL At least one measurable lesion CT creatinine &lt; 2.5 Informed consent sign Social insurance Pregnancy breastfeed Serious illness comorbidity risk assess History cancer within 5 year except skin cancer melanoma carcinoma situ cervix Presence antiantibodies patient previously receive antibody Known hypersensitivity antibody proteins intellectual disability sign inform consent Not control diabetes Persons protect law</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ImmunoTEP</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>